BB Biotech AG

07/23/2021 | Press release | Distributed by Public on 07/22/2021 23:08

Interim report as at June 30, 2021

The corona pandemic continues to hold the world in its grip. The biotech industry, on the other hand, is additionally moved by a new drug, the Alzheimer's drug Aduhelm from Biogen. A few weeks ago, this drug received FDA approval in June of this year. Find out more in a conversation with Dr. Daniel Koller, Head Investment Team, on the occasion of the half-year figures of BB Biotech AG 2021.